Alexandr Ceasovschih, Assist. Prof., PhD

Dr. Alexandr Ceasovschih, Assist. Prof., PhD

Grigore T. Popa University of Medicine and Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VMVictoria Mutruc
Victoria Mutruc
CBCristina Bologa
Cristina Bologa
VSVictorita Sorodoc
Victorita Sorodoc
Alexandr Ceasovschih, Assist. Prof., PhDAlexandr Ceasovschih, Assist. Prof., PhD
Alexandr Ceasovschih, Assist. Prof., PhD
BMBianca-Codrina Morarasu
Bianca-Codrina Morarasu
CLCatalina Lionte
Catalina Lionte
Cardiovascular, renal, and metabolic diseases are pathophysiologically interdependent, posing a significant global health challenge and being associated with a substantial increase in morbidity and mortality. In 2023, the American Heart Association (AHA) defined this complex network of interconnected health conditions as the cardiovascular–kidney–metabolic (CKM) syndrome. This syndrome is based on common pathophysiological mechanisms, including chronic inflammation, oxidative stress, hyperglycemia and insulin resistance, activation of the renin–angiotensin–aldosterone system (RAAS), and neurohormonal dysfunction, which trigger a vicious cycle where the impairment of one organ contributes to the progressive deterioration of the others. An integrated approach to these conditions, rather than treating them as separate entities, supports a holistic management strategy that helps to reduce the burden on public health and improve patients’ quality of life. Existing management focuses on lifestyle modification, glycemic and lipid control, and the use of nephroprotective and cardioprotective therapies. This narrative review aims to synthesize and contextualize existing information on the complex interactions between these systems and on diagnostic approaches, as well as to provide an overview of the available therapeutic options.

24 August 2025 in Pharmacological Research
Verified
Journal Article
Open access
Alexandr Ceasovschih, Assist. Prof., PhDAlexandr Ceasovschih, Assist. Prof., PhD
Alexandr Ceasovschih, Assist. Prof., PhD
AAAndreea Asaftei
Andreea Asaftei
MLMaria Giovanna Lupo
Maria Giovanna Lupo
Stanislav KotlyarovStanislav Kotlyarov
Stanislav Kotlyarov
HBHana Bartušková
Hana Bartušková
MBMaciej Banach
Maciej Banach
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating sarcopenic obesity, particularly in older or frail individuals with limited muscular reserves. This review critically examines current data on the effects of GLP-1 RAs on body composition, explores the underlying pathophysiological mechanisms of skeletal muscle wasting, and offers evidence-based strategies for attenuating these potential adverse outcomes. While GLP-1 RAs therapy remains central to obesity management, optimizing its use through early recognition and management of associated risks is essential to preserve muscular health, patient functional status and quality of life.

15 May 2024 in Atherosclerosis
Verified
Journal Article
Closed access
FBFotios Barkas
Fotios Barkas
YSYusuf Ziya Sener
Yusuf Ziya Sener
PGPelin Arabacilar Golforoush
Pelin Arabacilar Golforoush
AKAzin Kheirkhah
Azin Kheirkhah
ERElena Rodriguez-Sanchez
Elena Rodriguez-Sanchez
FPFlorentina Porsch
Florentina Porsch

12 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VSVictorita Sorodoc
Victorita Sorodoc
LILucia Indrei
Lucia Indrei
Catinca DobroghiiCatinca Dobroghii
Catinca Dobroghii
AAAndreea Asaftei
Andreea Asaftei
Alexandr Ceasovschih, Assist. Prof., PhDAlexandr Ceasovschih, Assist. Prof., PhD
Alexandr Ceasovschih, Assist. Prof., PhD
LȘLaurențiu Șorodoc
Laurențiu Șorodoc
Amiodarone, a bi-iodinated benzofuran derivative, is among the most commonly used antiarrhythmic drugs due to its high level of effectiveness. Though initially categorized as a class III agent, amiodarone exhibits antiarrhythmic properties across all four classes of antiarrhythmic drugs. Amiodarone is highly effective in maintaining sinus rhythm in patients with paroxysmal atrial fibrillation while also playing a crucial role in preventing a range of ventricular arrhythmias. Amiodarone has a complex pharmacokinetic profile, characterized by a large volume of distribution and a long half-life, which can range from several weeks to months, resulting in prolonged effects even after discontinuation. Side effects may include thyroid dysfunction, pulmonary fibrosis, and hepatic injury, necessitating regular follow-ups. Additionally, amiodarone interacts with several drugs, including anticoagulants, which must be managed to prevent adverse effects. Therefore, a deep understanding of both oral and intravenous formulations, as well as proper dosage adjustments, is essential. The aim of this paper is to provide a comprehensive and updated review on amiodarone’s indications, contraindications, recommended dosages, drug interactions, side effects, and monitoring protocols.

Verified
Journal Article
Open access
PDF file
ADAlexandra-Diana Diaconu
Alexandra-Diana Diaconu
Alexandr Ceasovschih, Assist. Prof., PhDAlexandr Ceasovschih, Assist. Prof., PhD
Alexandr Ceasovschih, Assist. Prof., PhD
VSVictorita Sorodoc
Victorita Sorodoc
CPCristina Pomîrleanu
Cristina Pomîrleanu
CLCatalina Lionte
Catalina Lionte
CACODRINA MIHAELA ANCUTA
CODRINA MIHAELA ANCUTA
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that can lead to ankylosis by secondary ossification of inflammatory lesions, with progressive disability and a significant impact on quality of life. It is also a risk factor for the occurrence of comorbidities, especially cardiovascular diseases (CVDs), mood disorders, osteoporosis, and malignancies. Early diagnosis and treatment are needed to prevent or decrease functional decline and to improve the patient’s prognosis. In respect of axSpA, there is an unmet need for biomarkers that can help to diagnose the disease, define disease activity and prognosis, and establish personalized treatment approaches. The aim of this review was to summarize the available information regarding the most promising biomarkers for axSpA. We classified and identified six core categories of biomarkers: (i) systemic markers of inflammation; (ii) molecules involved in bone homeostasis; (iii) HLA-B27 and newer genetic biomarkers; (iv) antibody-based biomarkers; (v) microbiome biomarkers; and (vi) miscellaneous biomarkers. Unfortunately, despite efforts to validate new biomarkers, few of them are used in clinical practice; however, we believe that these studies provide useful data that could aid in better disease management.

3 August 2022 in Life
Verified
Journal Article
Open access
PDF file
VSVictorita Sorodoc
Victorita Sorodoc
OSOana Sirbu
Oana Sirbu
CLCatalina Lionte
Catalina Lionte
RHRaluca Ecaterina Haliga
Raluca Ecaterina Haliga
ASAlexandra Stoica
Alexandra Stoica
LSLaurentiu Sorodoc
Laurentiu Sorodoc
In cancer survivors, cardiac dysfunction is the main cause of mortality. Cardiotoxicity represents a decline in cardiac function associated with cancer therapy, and the risk factors include smoking, dyslipidemia, an age of over 60 years, obesity, and a history of coronary artery disease, diabetes, atrial fibrillation, or heart failure. Troponin is a biomarker that is widely used in the detection of acute coronary syndromes. It has a high specificity, although it is not exclusively associated with myocardial ischemia. The aim of this paper is to summarize published studies and to establish the role of troponin assays in the diagnosis of cardiotoxicity associated with various chemotherapeutic agents. Troponin has been shown to be a significant biomarker in the diagnosis of the cardiac dysfunction associated with several types of chemotherapeutic drugs: anthracyclines, anti-human epidermal growth factor receptor 2 treatment, and anti-vascular endothelial growth factor therapy. Based on the data available at this moment, troponin is useful for baseline risk assessment, the diagnosis of cardiotoxicity, and as a guide for the initiation of cardioprotective treatment. There are currently clear regulations regarding the timing of troponin surveillance depending on the patient’s risk of cardiotoxicity and the type of medication administered, but data on the cut-off values of this biomarker are still under investigation.